Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa malaria sporozoite challenge study of AdCh63/MVA AMA1, MSP1, and ME-TRAP vaccines
2010-018341-56Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Mar 2010
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of adch63 ama1, MVA AMA1 vaccine, AdCh63 MSP1, mva msp1 vaccine, ChAd63 ME-TRAP and 1 more in malaria (4 arms), sponsored by University of Oxford. Primary endpoints: Protective efficacy against malaria infection and Time to parasitaemia. Started Mar 2010; status: completed.
02
Drugs
adch63 ama1MVA AMA1 vaccineAdCh63 MSP1mva msp1 vaccineChAd63 ME-TRAP
03
Conditions
malaria
Beyond the preview
Go deeper on 2010-018341-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018341-56.